Location: Cambridge,MA, USA
This role is considered On-Site.
Overview
The candidate in this position will join an interdisciplinary research group focused on driving mechanistic understanding of RNAi biology and extrahepatic siRNA delivery. The role requires background in biological sciences and technical skillsets in in vitro cell culture as well as molecular and biochemical assays. The role requires strong interpersonal skills, the capacity to multi-task, and the ability to learn and master new techniques in the field of RNAi. We seek someone who is detail-oriented, enthusiastic, and who will flourish in a goal-driven collaborative environment.
This position is onsite and will be primarily located at 675 W Kendall St Cambridge MA.
Key Responsibilities
* The candidate will engage in a variety of investigative, mechanistic siRNA research efforts to evaluate RNAi compounds, utilizing biochemical, molecular, and cell-based assays.
* Willingness to learn and execute new techniques to support in vitro and in vivo studies.
* Experimental design and troubleshooting, data analysis/interpretation, and presentation of results to key stakeholders within the Research organization.
Qualifications
* BS/MS in Biology, Biochemistry, or related field with 3-5 years of work experience, preferably in an industrial setting.
* Working knowledge of nucleic acid-based therapies (siRNA, ASO, CRISPR)
* Proficiency in mammalian cell culture (maintenance, transfection/stable selection) and molecular biology assays for RNA/DNA/protein quantification (qPCR, Western blotting, ELISA, immunoprecipitations).
* Willingness to learn and/or support in vivo rodent studies is preferred.
* Excellent lab technique and ability to work independently.
* Strong interpersonal skills and excellent communication skills (written and oral) are required
About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by interfering with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.
Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, weve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazines Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK among others.
At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.